SANTA BARBARA, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, today announced the closing of its follow-on public offering of 3,000,000 shares of its common stock at a price to the public of $22.00 per share. This public offering resulted in total aggregate gross proceeds of approximately $66.0 million, before underwriting discounts and commissions and offering expenses. All of the shares in the offering were sold by Sientra. In addition, Sientra has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock on the same terms and conditions.
Piper Jaffray and Stifel acted as joint book-running managers for the offering. Leerink Partners and William Blair acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2015. Copies of the effective registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov. The offering of these securities were made only by means of a prospectus, copies of which may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924, and by e-mail at [email protected]; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products.
CONTACT: Investor Contacts:
The Ruth Group
Nick Laudico
(646) 536-7030
[email protected]